Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529130 | 1.00 | BRD4 (0.37) | BRD4ALOX5 | |
| SCHEMBL12714638 | 1.00 | BRD4 (0.37) | BRD4ALOX5 | |
| Hydrochloric Acid SCHEMBL15191411 | 0.97 | BRD4 (0.36) | BRD4ALOX5 | |
| Hydrochloric Acid SCHEMBL15191371 | 0.97 | BRD4 (0.36) | BRD4ALOX5 | |
| Hydrochloric Acid SCHEMBL529660 | 0.97 | BRD4 (0.36) | BRD4ALOX5 | |
| Hydrochloric Acid SCHEMBL15191068 | 0.97 | BRD4 (0.36) | BRD4ALOX5 | |
| Acetic Acid SCHEMBL528980 | 0.87 | ALOX5 (0.41) | BRD4ALOX5 | |
| Acetic Acid SCHEMBL15190863 | 0.87 | ALOX5 (0.41) | BRD4ALOX5 | |
| SCHEMBL16369219 | 0.86 | BRD4 (0.37) | BRD4ALOX5 | |
| SCHEMBL659645 | 0.86 | ALOX5 (0.36) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | claimed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | claimed |
| US-10544138-B2 | Tricyclic kinase inhibitors of MELK and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190084977-A1 | TRICYCLIC KINASE INHIBITORS OF MELK ANDS METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| CN-104968345-B | 1, 5-naphthyridine derivatives and ME L K inhibitors containing 1, 5-naphthyridine derivatives | 肿瘤疗法科学股份有限公司 | 2018-05-08 | — | — | CN | disclosed |
| US-20180009787-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-11 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| EP-1727812-B1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INT (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-7262206-B2 | Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| EP-1727812-A1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005087761-A1 | NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084977-A1 | TRICYCLIC KINASE INHIBITORS OF MELK ANDS METHODS OF USE | MELK, MKNK1, BMP2K | BRD4 335/4885ALOX5 4703/4885 |
| US-10023558-B2 | Compounds | SERPINB1, ELANE, MPO | BRD4 1226/4885ALOX5 314/4885 |
| US-20180009787-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | BRD4 1216/4885ALOX5 496/4885 |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3B, GSK3A, CSNK1G3 | BRD4 1489/4885ALOX5 1363/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | BRD4 2137/4885ALOX5 3173/4885 |
| US-10544138-B2 | Tricyclic kinase inhibitors of MELK and methods of use | MELK, MKNK1, BMP2K | BRD4 313/4885ALOX5 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.